Digene HPV DNA Pap Test Impact Should Be Assessed Postmarket – Panel
Digene's HPV DNA Pap test should be approved as a primary screen for cervical cancer contingent upon clarification of clinical utility using existing data, FDA's Microbiology Devices Panel concluded in a 6-2 vote March 8 in Gaithersburg, Maryland
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
